Adamis Pharmaceuticals Corporation
| NASDAQ: ADMP | Healthcare / Drug Manufacturers / USA |
| 0.1152 | -0.0048 | -4.00% | Vol 219.66K | 1Y Perf -80.01% |
| Mar 24th, 2023 12:28 DELAYED |
| BID | 0.1152 | ASK | 0.1196 | ||
| Open | 0.1164 | Previous Close | 0.1200 | ||
| Pre-Market | 0.12 | After-Market | - | ||
| 0.00 -1.67% | - - |
| Target Price | 1.25 | Analyst Rating | — 0.00 | |
| Potential % | 985.07 | Finscreener Ranking | ★ — - | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ☆ 30.18 | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★ 34.92 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.99 | Earnings Rating | Buy | |
| Market Cap | 19.18M | Earnings Date | 15th May 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.32 | |
| Beta | 1.19 |
Today's Price Range 0.11090.1200 | 52W Range 0.09920.6350 | 5 Year PE Ratio Range -2.30-2.70 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 9.09% | ||
| 1 Month | -56.83% | ||
| 3 Months | -23.08% | ||
| 6 Months | -48.98% | ||
| 1 Year | -80.01% | ||
| 3 Years | -69.23% | ||
| 5 Years | -96.57% | ||
| 10 Years | -98.91% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -82.75 | |||
ROE last 12 Months | -199.24 | |||
ROA (5Y Avg) | -44.15 | |||
ROA last 12 Months | -126.88 | |||
ROC (5Y Avg) | -87.71 | |||
ROC last 12 Months | -164.56 | |||
Return on invested Capital Q | -86.67 | |||
Return on invested Capital Y | -28.39 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 0.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.90 | ||||
| 10.38 | ||||
| 11.62 | ||||
| - | ||||
| -1.20 | ||||
| -0.21 | ||||
| 10.38 | ||||
| 0.02 | ||||
| 27.56M | ||||
| Forward PE | -1.83 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.40 | ||||
| 1.10 | ||||
| 0.02 | ||||
| 0.15 | ||||
| -79.70 | ||||
| Leverage Ratio | 2.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -271.40 | ||||
| -2 090.60 | ||||
| -1 988.50 | ||||
| -236.20 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.61M | ||||
| 0.02 | ||||
| -28.04 | ||||
| -5.39 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.03 | - |
| Q02 2022 | -0.04 | -0.06 | -50.00 |
| Q01 2022 | -0.03 | -0.07 | -133.33 |
| Q03 2021 | -0.06 | -0.03 | 50.00 |
| Q04 2020 | - | -0.16 | - |
| Q03 2020 | -0.04 | -0.10 | -150.00 |
| Q02 2020 | -0.07 | -0.13 | -85.71 |
| Q01 2020 | -0.05 | -0.10 | -100.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.04 | 0.00 | - |
| 9/2022 QR | -0.03 | 0.00 | - |
| 12/2022 FY | -0.15 | -15.38 | Negative |
| 12/2023 FY | -0.06 | -20.00 | Negative |
| Next Report Date | 15th May 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 219.66K |
| Shares Outstanding | 166.48K |
| Shares Float | 149.41M |
| Trades Count | 453 |
| Dollar Volume | 25.30K |
| Avg. Volume | 1.61M |
| Avg. Weekly Volume | 1.35M |
| Avg. Monthly Volume | 2.34M |
| Avg. Quarterly Volume | 1.15M |
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock closed at 0.12 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 712.26K shares and market capitalization of 19.18M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 171 people. Adamis Pharmaceuticals Corporation CEO is Dennis J. Carlo.
The one-year performance of Adamis Pharmaceuticals Corporation stock is -80.01%, while year-to-date (YTD) performance is -29.12%. ADMP stock has a five-year performance of -96.57%. Its 52-week range is between 0.0992 and 0.635, which gives ADMP stock a 52-week price range ratio of 2.99%
Adamis Pharmaceuticals Corporation currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 10.38, a price-to-sale (PS) ratio of 11.62, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -126.88%, a ROC of -164.56% and a ROE of -199.24%. The company’s profit margin is -%, its EBITDA margin is -1 988.50%, and its revenue ttm is $2.61 Million , which makes it $0.02 revenue per share.
Of the last four earnings reports from Adamis Pharmaceuticals Corporation, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Adamis Pharmaceuticals Corporation’s next earnings report date is 15th May 2023.
The consensus rating of Wall Street analysts for Adamis Pharmaceuticals Corporation is — (0), with a target price of $1.25, which is +985.07% compared to the current price. The earnings rating for Adamis Pharmaceuticals Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adamis Pharmaceuticals Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Adamis Pharmaceuticals Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 23.51, ATR14 : 0.02, CCI20 : -64.85, Chaikin Money Flow : -0.55, MACD : -0.03, Money Flow Index : 20.40, ROC : -23.08, RSI : 34.14, STOCH (14,3) : 30.06, STOCH RSI : 1.00, UO : 38.95, Williams %R : -69.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adamis Pharmaceuticals Corporation in the last 12-months were: Dennis J. Carlo (Option Excercise at a value of $0)
Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose. Its SYMJEPI (epinephrine) Injection products are used in the emergency treatment of acute allergic reactions, including anaphylaxis.
CEO: Dennis J. Carlo
Telephone: +1 858 997-2400
Address: 11682 El Camino Real, San Diego 92130, CA, US
Number of employees: 171
